Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of golidocitinib monotherapy in relapsed or refractory T-cell large granular lymphocytic leukemia
ChiCTR2600134749Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in T-cell large granular lymphocytic leukemia, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective response rate at 3 cycles. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on ChiCTR2600134749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134749.